JSAM
MLYS icon

J. Safra Asset Management’s Mineralys Therapeutics MLYS Stock Holding History

J. Safra Asset Management’s Portfolio MLYS Stock Details MLYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$6.77K Buy
250
+169
+209% +$4.96K ﹤0.01% 417
2025
Q4 		$2.94K Buy
+81
New +$3.25K ﹤0.01% 501

Other funds holding MLYS

CP
Catalys Pacific Tokyo, Japan $231M AUM 83.19% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

J. Safra Asset Management's MLYS Position: Q1 2026 in Review

J. Safra Asset Management increased its Mineralys Therapeutics (MLYS) stake by 209% in Q1 2026, buying an estimated $4.96K and bringing the position to 250 shares worth $6.77K. The position accounts for ﹤0.01% of the portfolio, ranked #417.

J. Safra Asset Management first reported a position in MLYS in Q4 2025 and has held it in 2 quarters since. 214 funds tracked by Wall St. Rank hold MLYS as of Q1 2026.

  • J. Safra Asset Management held 250 shares of Mineralys Therapeutics worth $6.77K as of Q1 2026.
  • J. Safra Asset Management bought 169 Mineralys Therapeutics shares in Q1 2026, an estimated $4.96K.
  • Mineralys Therapeutics made up ﹤0.01% of J. Safra Asset Management's portfolio in Q1 2026, its #417 holding.
  • J. Safra Asset Management first reported a position in Mineralys Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • 214 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q1 2026.

Based on J. Safra Asset Management's 13F filing for Q1 2026, filed 4 May 2026.